Scholarlink

<p>PTEN deficiency is frequently observed in various cancers, including triple-negative breast cancer. However, PTEN loss-of-function mutations are not directly druggable, necessitating a synthetic lethality approach for treating PTEN-deficient tumors. Utilizing combinatorial CRISPR screening, we identified ICMT (isoprenylcysteine carboxylmethyltransferase) loss as synthetic lethal with PTEN deficiency. Genetic or pharmacological inhibition of ICMT effectively reversed cellular transformation induced by PTEN loss. Mechanistically, ICMT loss disrupts the positive feedback loop involving PIP3-PIP3-dependent guanine nucleotide exchange factor (GEF)-Rac1-PI3K by increased physical association of Rac1 and RhoGDI, inhibiting Rac1 activity and stability. Disruption of this feedback loop attenuates epithelial-mesenchymal transition and reduces the cancer stem cell population. Additionally, ICMT loss leads to the accumulation of aggregated proteins, which activates the unfolded protein response (UPR) signaling, ultimately resulting in cell death. Cysmethynil, an ICMT inhibitor, effectively suppresses PTEN-mutant cancer growth in xenograft models. Collectively, our study establishes ICMT as a promising therapeutic target for treating PTEN-mutant cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Byung-Sun Park,
  • Jaeyeol Kim,
  • Dong-Chan Seo,
  • Ga-Eun Choi,
  • Jin-Ju Seo,
  • Seung Eun Lee,
  • Tackhoon Kim

摘要

PTEN deficiency is frequently observed in various cancers, including triple-negative breast cancer. However, PTEN loss-of-function mutations are not directly druggable, necessitating a synthetic lethality approach for treating PTEN-deficient tumors. Utilizing combinatorial CRISPR screening, we identified ICMT (isoprenylcysteine carboxylmethyltransferase) loss as synthetic lethal with PTEN deficiency. Genetic or pharmacological inhibition of ICMT effectively reversed cellular transformation induced by PTEN loss. Mechanistically, ICMT loss disrupts the positive feedback loop involving PIP3-PIP3-dependent guanine nucleotide exchange factor (GEF)-Rac1-PI3K by increased physical association of Rac1 and RhoGDI, inhibiting Rac1 activity and stability. Disruption of this feedback loop attenuates epithelial-mesenchymal transition and reduces the cancer stem cell population. Additionally, ICMT loss leads to the accumulation of aggregated proteins, which activates the unfolded protein response (UPR) signaling, ultimately resulting in cell death. Cysmethynil, an ICMT inhibitor, effectively suppresses PTEN-mutant cancer growth in xenograft models. Collectively, our study establishes ICMT as a promising therapeutic target for treating PTEN-mutant cancers.